Galen Clinic
- Address
- lock Available on a paid plan
Generalized Myasthenia Gravis
At the Galen Clinic researchers are evaluating the novel agent remibrutinib as a potential treatment for generalized Myasthenia Gravis. The study aims to determine whether the drug can improve patients’ daily functioning and reduce disease activity compared with standard care.
- Immune‑mediated neuromuscular disorder
- Patient‑reported outcome measures
- Safety and tolerability assessment
The trial reflects the clinic’s commitment to advancing therapies for nervous system diseases in Warsaw, Poland.
Chronic Inflammatory Demyelinating Polyneuropathy
A separate program at the Galen Clinic investigates empasiprubart, an innovative therapeutic option for adults with Chronic inflammatory demyelinating polyneuropathy (CIDP). The research compares the new drug with placebo and with standard intravenous immunoglobulin (IVIg) to see if it can better restore functional ability.
- Peripheral nerve demyelination
- Alternative to IVIg therapy
- Functional capacity evaluation
These studies illustrate the site’s focus on improving outcomes for patients with rare neurological conditions in Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Galen Clinic
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Empasiprubart | 2 | Unknown | 2026-01-07 | 2026-03-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.